Ruling in SCOTUS mifepristone case could lead to endless litigation, industry says
Industry groups, members of Congress and state legislatures are among the wave of parties that asked the Supreme Court on Tuesday to preserve the FDA’s regulations around the abortion pill mifepristone as the court gears up to hear oral arguments in the high-profile case this spring.
More than 30 amicus briefs, drafted by groups ranging from lawmakers to faith groups, were filed Tuesday in the closely-watched case brought by the conservative advocacy organization Alliance for Hippocratic Medicine that seeks to restrict how the FDA can regulate mifepristone. Industry groups who filed briefs underscore that the Fifth Circuit Court of Appeals’ ruling, which reined in the FDA’s regulation of the pill, could severely destabilize the industry and open the door to endless litigation to determine how products can be prescribed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.